{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling in tumors",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling",
          "line_ref": "L42"
        },
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings"
    },
    {
      "claim_id": "C02",
      "claim": "Intratumoral mRNA vaccination increases the fraction of tumor proteins represented in the immunopeptidome and MHC-I peptidome",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        }
      ],
      "caveat": "The specific expansion magnitude may vary across different tumor models and the effect was strongest in specific model systems"
    },
    {
      "claim_id": "C03",
      "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in metastatic patients receiving ICI treatment",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "Human vaccinated subgroup: 43 patients",
          "line_ref": "L22"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely, and vaccination timing relative to ICI initiation varied across patients"
    },
    {
      "claim_id": "C04",
      "claim": "Type I interferon signaling is necessary for the observed mRNA vaccine sensitization benefit",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit",
          "line_ref": "L39"
        },
        {
          "quote": "Interferon-associated antigen processing and presentation pathways increase",
          "line_ref": "L43"
        }
      ],
      "caveat": "This causal dependency was demonstrated in mouse models and may not directly translate to all human tumor contexts"
    },
    {
      "claim_id": "C05",
      "claim": "Combined intratumoral mRNA vaccination with checkpoint blockade improves tumor control compared to either monotherapy",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Vaccine-only treatment did not produce durable tumor control in non-immunogenic models",
          "line_ref": "L36"
        },
        {
          "quote": "ICI-only treatment had limited activity in low-immunogenic baseline settings",
          "line_ref": "L37"
        }
      ],
      "caveat": "The improved control was observed in preclinical murine models and requires prospective randomized studies before clinical protocol changes are justified"
    }
  ]
}
